EMA Authorised: Balversa (Erdafitinib) — Janssen-Cilag International N.V.

View source ↗

Summary

Authorised status for Balversa (Erdafitinib) by EMA for urologic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urologic Neoplasms

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Status: Authorised. Therapeutic area: Urologic Neoplasms. MAH: Janssen-Cilag International N.V.. Decision date: 24/04/2026